Medical Education, Clinical Tools, and Events

Medical Education, Clinical Tools, and Events

Myeloma Canada encourages access to evidence‑based medical education for healthcare professionals involved in the
care of people with multiple myeloma. This section brings together trusted learning programs developed by continuing medical education providers.

Our goal is to provide the broader care community with practical, up‑to‑date education that improves early detection, strengthens referral pathways, and supports the safe delivery of innovative therapies across diverse care settings.

Explore the tabs below to access educational programs, self‑assessment modules, clinical tools and events.

Multiple myeloma: primary care management and referral

Myeloma Canada has partnered with Queen’s University to deliver an accredited, on‑demand medical education program.

Learning outcomes

Upon completion of this course, you will be able to:

Identify the common signs and symptoms of multiple myeloma.
Assess patients with signs and symptoms suggestive of multiple myeloma.
Initiate referral as needed based on relevant information gathered from the initial multiple myeloma work-up.
Discuss the monitoring and management of symptoms of diagnosed multiple myeloma or precursor conditions.

Accreditation

5 self-assessment learning hours for the Royal College;
5 Mainpro+ credits in the Self-Learning Category for the College of Family Physicians of Canada;
certificate for 1.5 hours of professional development for all health professions.

Access to the course is free for the first 800 learners thanks to the independent educational support from Green for Life, Binding Site, and Sebia Diagnostics.

Access the course page

Multiple Myeloma Immunotherapy: Foundation, Optimal Management, and Interprofessional Collaboration

This course explores BCMA-targeted therapies for relapsed/refractory multiple myeloma, covering treatment mechanisms, toxicity management, and interprofessional collaboration.

Accreditation

This online program has two modules, each accredited by Queen’s University for 1 hour in the Self-Assessment (Section 3) category for the Royal College and provides a certificate for 1 hour of professional development for all health professions.

Access to the course is free for the first 800 learners thanks to the independent educational support from Green for Life, Binding Site, and Sebia Diagnostics.

Access the course page

Identification and Management of Cytokine Release Syndrome and Immune Effector Cell-associated Neurotoxicity Syndrome

Identify early warning signs, initiate timely and appropriate interventions, and optimize care.

Accreditation

Royal College Specialists: This program is an accredited Self-Assessment Program (Section 3) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada, and approved by the Queen’s University Continuing Professional Development team. You may claim a maximum of 0.5 hours.
Healthcare Professionals: This is a professional learning activity which provides up to 0.5 hours of Continuing Education.

Access the course page

A.C.T.I.O.N in Myeloma: Applied Clinical Thinking in Oncology Navigation

This 1-hour program for pharmacists and nurses focuses on optimizing eye-related side effect management and patient counselling for patients receiving treatment for relapsed/refractory multiple myeloma with antibody-drug conjugates (ADCs).

Learning objectives

Share real-life insights on factors that contribute to treatment decision-making when initiating new myeloma therapies.
Apply practical considerations related to dosing and administration of novel anti-BCMA therapies, including ADCs, to support evidence-based, patient-centred treatment management.
Demonstrate how to streamline collaboration with other healthcare professionals, with a focus on adverse event management.

Accreditation

The Canadian Council on Continuing Education in Pharmacy (CCCEP) has accredited this program for 1.75-CEUs.
The Canadian Nurses Association (CNA) has accredited this program for 1.00-CEU.

Access the course page

mEYEloma: Eye Care Professionals’ Role in Monitoring Ocular Effects of Oncology Treatment

This 45-minute on-demand program for eye care professionals focuses on eye-related side effectsProblems that occur due to drugs used for disease treatment. Common side effects of cancer treatment are fatigue, nausea, vomiting, decreased blood cell counts, hair loss, and mouth sores. associated with a new treatment for multiple myeloma, a form of blood cancerA term for diseases in which malignant cells divide without control. Cancer cells can invade nearby tissues and spread through the bloodstream and lymphatic system to other parts of the body..

Learning objectives

By the end of this program participants will be able to:
Review cancer therapies and the eye-related side effects associated with antibody-drug conjugates (ADCs).
Identify and manage ocular adverse events related to ADCs through collaborative decision-making and patient case discussions.
Differentiate the roles of eye care professionals and oncologists in managing eye-related side effects and foster effective interdisciplinary collaboration.

Accreditation

This program has been accredited by the Council on Optometric Practitioner Education (COPE) for 1.00 credit hours.

Access the course page

Self‑assessment modules are designed to reinforce core concepts in the diagnosisThe process of identifying a disease by its signs and symptoms., monitoring, and management of multiple myeloma. They can be completed at any time and are suitable for all healthcare professionals involved in myeloma care.

Multiple Myeloma: Consensus Guidelines Self-Assessment

Myeloma Canada has partnered with Queen’s University to deliver an accredited, on demand medical education program.
In this program you will review one or more consensus papers developed by a Canadian Consensus Guideline Consortium led by Myeloma Canada. You will then self-assess your practice and knowledge against these gold-standard guidelines using knowledge-testing questions. These questions will provide feedback and help guide adjustments to your practice.
The Scientific Planning Committee would like to thank Apotex Canada for their generous support through an independent medical education grant.

Accreditation

This learning program is a guided self-assessment activity that provides Royal College Section 3: Self-Assessment credits as well as Mainpro+ Certified Assessment credits as defined by the College of Family Physicians of Canada.

Access the course page

This section contains downloadable, practical resources to support clinical decision‑making, toxicity recognition, dosing, monitoring, and coordinated management.

Use of Belantamab Mafodotin in the Management of Relapsed/Refractory Multiple Myeloma

Canadian Institute for the Transfer of Knowledge (CITE) has developed clinical guidance outlining practical recommendations for the safe and effective use of belantamab mafodotin in adults with relapsed/refractory multiple myeloma. This resource includes dosing considerations, ocular toxicity monitoring, dose‑modification strategies, and supportive‑care measures to minimize treatment‑related complications.

Download the clinical tool

Use of Bispecific T-cell Engagers in the Management of Relapsed/Refractory Multiple Myeloma

Canadian Institute for the Transfer of Knowledge (CITE) has developed clinical guidance to support the safe and effective use of bispecific T‑cellThe basic unit of any living organism. engagers in relapsed/refractory multiple myeloma. This resource provides practical recommendations for step‑up dosing, restart rules after treatment delays, infection prophylaxis, immunoglobulin monitoring, and supportive‑care strategies. It also includes concise algorithms for recognizing and managing CRS and ICANS to support rapid, appropriate intervention.

Download the clinical tool

This section features educational events offering timely updates for healthcare professionals involved in the care of people living with multiple myeloma.

Princess Margaret Cancer Centre Multiple Myeloma Day

Princess Margaret Cancer Centre’s Multiple Myeloma Day presents the latest developments in the management of myeloma and related plasmaThe liquid part of the blood in which red blood cells, white blood cells, and platelets are suspended. cell disorders.

Date: May 22, 2026
Time: 8:00 am – 2:15 pm
Location: The Estates of Sunnybrook, 135 Armistice Drive, North York, ON M4N 1J8

Target audience
Community health practitioners including physicians, nurses, pharmacists, trainees, and other health care providers who are involved in the care of patients with plasma cell disorders will find this program of benefit.

More information